Bacterial susceptibilities to piperacillin/tazobactam in a tertiary care hospital: 5-year review

Journal of Chemotherapy

Volumn 15, Issue 1, 2003, Pages 27-30

  Platsouka, E ^a   Zissis, N P ^b   Portolos, J ^a   Paniara, O ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b Medical Department   (Greece)

Author keywords

Agents; Antibacterial resistance; Cefepime; Imipenem; Piperacillin tazobactam; lactam

Indexed keywords

AMOXICLAV; ANTIBIOTIC AGENT; BETA LACTAM DERIVATIVE; CEFEPIME; CEFTRIAXONE; IMIPENEM; PIPERACILLIN; TAZOBACTAM; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; CONTROLLED STUDY; DRUG USE; HOSPITAL; IN VITRO STUDY; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW;

EID: 0242669310     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.1.27     Document Type: Review

References (13)

1. Murray BE. Can antibiotic resistance be controlled? N Engl J Med 1994; 330: 1229-1230.
2. Platsouka E, Zissis N, Constantoulaki S, Paniara O. Comparative in vitro evaluation of piperacillin/tazobactam in tertiary care hospital. J Chemother 1997; 9: 336-340.
3. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4, NCCLS, Villanova, PA, 1998.
4. Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000; 21: 455-458.
5. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994; 330: 1240-1241.
6. Rahal JJ. Extended-spectrum β-lactamases: how big is the problem? Clin Microbiol Infect 2000; 6 (suppl 2): 2-6.
7. Hancock REW, Bellido F. Antibacterial in vitro activity of fourth generation cephalosporins. J Chemother 1996; 8 (Suppl 2): 31-36.
8. Cavallo JD, Leblanc F, Fabre R, Fourticq-Esqueoute A. Surveillance de la sensibilité de Pseudomonas aeruginosa aux antibiotiques en France et distribution des mecanismes de resistance aux betalactamines: étude GERPB 1999. Pathol Biol (Paris) 2001; 49: 534-539.
9. Sader HS, Jones RN, Gales AC, Winokur P, Kugler KC, Pfaller MA, Doern GV, and the SENTRY Latin America Study Group. Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY antimicrobial surveillance program (1997). Diagn Microbiol Infect Dis 1998; 32: 289-301.
10. Marshall SA., Aldridge KE, Allen SD, Fuchs PC, Gerlach EH, Jones RN. Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five years. Diag Microbiol Infect Dis 1995; 21: 153-168.
11. Varotto F, Di Maria G, Azzaro R, et al. An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacillin/tazobactam, ceftazidirne and ceftriaxone. J Chemother 2001; 13: 413-423.
12. Mokaddas E, Rotimi VO, Sanyal SC. In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial Gram-negative pathogens isolated from burn patients. J Chemother 1998; 10: 208-214.
13. Fluit AC, Verhoef J, Schimtz FJ, The European SENTRY participants. Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European University Hospitals participating in the European Arm of the SENTRY antimicrobial surveillance program 1997-1998. Eur J Clin Microbiol Infect Dis 2001; 20: 617-625.